KKR partners with LGC to facilitate future expansion and growth

Private equity firm KKR has agreed to buy life sciences measurement and testing firm LGC from London-based investment group Bridgepoint, for an undisclosed sum.

KKR will provide capital and operational support to facilitate future growth.

London-headquartered LGC said under the ownership of KKR it plans to 'continue the rapid development of the business', with a particular focus on the US and Asia. The company provides measurement products and services, including reference materials and proficiency testing, genomics reagents, instrumentation and services, and expert sample analysis and interpretation to customers in the pharmaceuticals, agricultural biotechnology, food, environment, government and academia sectors.

Tim Robinson, CEO, LGC said: 'We have ongoing, exciting growth opportunities across our entire business that will strengthen our solutions to our existing customers and help us expand into new markets and geographies. This is an exciting new phase in LGC's development and we believe that KKR’s network, market knowledge and support make them an ideal, new partner for our business.'

KKR said its global network, 'as well as its experience and deep relationships in the life sciences and healthcare sectors', will help LGC to grow.